The crude incidence of Hodgkin lymphoma (HL) in the European Union is 2.3, the mortality
0.4 cases/100 000/year. Young adults aged 20–40 years are most often affected. Slightly …

Classical Hodgkin lymphoma is one of the more frequent lymphomas and is generally
considered a highly curable disease with standard first-line chemotherapy and radiotherapy …

Background Incorporating brentuximab vedotin into the treatment of advanced-stage classic
Hodgkin's lymphoma improves outcomes in adult and pediatric patients. However …

This phase 1-2 study evaluated brentuximab vedotin (BV) combined with nivolumab (Nivo)
as first salvage therapy in patients with relapsed/refractory (r/r) classical Hodgkin lymphoma …

Background We tested interim positron-emission tomography–computed tomography (PET-
CT) as a measure of early response to chemotherapy in order to guide treatment for patients …

Background The intensive polychemotherapy regimen eBEACOPP (bleomycin, etoposide,
doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone in escalated …

PURPOSE Nivolumab, an anti–programmed death-1 monoclonal antibody, has
demonstrated frequent and durable responses in relapsed/refractory classic Hodgkin …

This phase 2 trial evaluated PET-adapted nivolumab alone or in combination with
ifosfamide, carboplatin, and etoposide (NICE) as first salvage therapy and bridge to …

Abstract In this phase 1/2 study, brentuximab vedotin (BV) and nivolumab (Nivo)
administered in combination were evaluated as initial salvage therapy in patients with …

The rarity of neoplastic cells in the biopsy imposes major technical hurdles that have so far
limited genomic studies in classical Hodgkin lymphoma (cHL). By using a highly sensitive …